A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant

Trial Profile

A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Pixantrone (Primary) ; Rituximab (Primary) ; Gemcitabine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PIX-R
  • Sponsors Cell Therapeutics; CTI BioPharma
  • Most Recent Events

    • 11 Jul 2018 Argentina,Brazil, Canada, Scotland were the planned location.
    • 09 Jul 2018 Primary endpoint has not been met. (Progression Free Survival (PFS)), according to a CTI BioPharma media release.
    • 03 May 2018 According to a CTI BioPharma media release, top-line results from this trial are event-driven and are expected in the third quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top